---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-014281"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T20:57:11.846074+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.

## Summary
- David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.
- Baker Tilly U.S., LLP ratified as auditor: 18,080,780 for, 7,381 against, 29,477 abstain.
- Reverse stock split approved (ratio 1-for-2 to 1-for-15): 16,176,833 for, 1,732,603 against.
- 2025 Equity Incentive Plan approved: 10,595,402 for, 1,473,888 against, 6,010,237 broker non-votes.
- Adjournment authorization approved: 16,811,725 for, 1,270,013 against.

## SEC filing metadata
- accession: 0001213900-25-014281
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/0001213900-25-014281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/ea0231253-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-014281
- JSON: https://secwatch.observer/filing/0001213900-25-014281.json
- Plain text: https://secwatch.observer/filing/0001213900-25-014281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.